Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Xeris Pharmaceuticals Inc

XERS
Current price
3.05 USD -0.1 USD (-3.17%)
Last closed 3.15 USD
ISIN US98422E1038
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 517 026 560 USD
Yield for 12 month +107.48 %
1Y
3Y
5Y
10Y
15Y
XERS
21.11.2021 - 28.11.2021

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois. Address: 180 North LaSalle Street, Chicago, IL, United States, 60601

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

4.67 USD

P/E ratio

Dividend Yield

Current Year

+163 914 000 USD

Last Year

+110 248 000 USD

Current Quarter

+48 065 000 USD

Last Quarter

+40 638 000 USD

Current Year

+124 426 000 USD

Last Year

+87 614 000 USD

Current Quarter

+37 565 000 USD

Last Quarter

+31 956 000 USD

Key Figures XERS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -24 999 000 USD
Operating Margin TTM -17.03 %
PE Ratio
Return On Assets TTM -7.04 %
PEG Ratio
Return On Equity TTM -617.16 %
Wall Street Target Price 4.67 USD
Revenue TTM 181 412 992 USD
Book Value -0.049 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 26.5 %
Dividend Yield
Gross Profit TTM 87 614 000 USD
Earnings per share -0.42 USD
Diluted Eps TTM -0.42 USD
Most Recent Quarter II 2024
Quarterly Earnings Growth YOY
Profit Margin -32.83 %

Dividend Analytics XERS

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History XERS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:1
Payout Ratio
Last Split Date 06.10.2021
Dividend Date

Stock Valuation XERS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 3.9097
Price Sales TTM 2.85
Enterprise Value EBITDA -3.3581
Price Book MRQ 3.3354

Financials XERS

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators XERS

For 52 weeks

1.46 USD 3.64 USD
50 Day MA 2.96 USD
Shares Short Prior Month 11 094 553
200 Day MA 2.48 USD
Short Ratio 8.56
Shares Short 11 565 005
Short Percent 7.95 %